Shandong Jincheng Pharmaceutical Group (300233.SZ): Jincheng Suzhi has been re-certified as a high-tech enterprise.

On April 21, Gelonghui reported that Shandong Jincheng Pharmaceutical Group (300233.SZ) announced that its wholly-owned subsidiary, Shanghai Jincheng Suzhi Pharmaceutical Co., Ltd. (referred to as "Jincheng Suzhi"), recently received the "High-tech Enterprise Certificate" issued jointly by the Shanghai Municipal Science and Technology Commission, the Shanghai Municipal Finance Bureau, and the Shanghai Municipal Taxation Bureau of the State Administration of Taxation. Issued date: December 26, 2024, Certificate number: GR202431002776, valid for three years.

Gelonghui FinanceApr 21 15:43

Express News | Shandong Jincheng Pharmaceutical Group: Subsidiary pharmaceutical for injectable cefotaxime sodium has been approved.

BreakingsApr 14 17:12

Shandong Jincheng Pharmaceutical Group (300233.SZ): The revenue from the company's synthetic biology products such as glutathione and S-adenosylmethionine directly exported to the USA accounts for about 2%.

On April 8, Gelonghui reported that Shandong Jincheng Pharmaceutical Group (300233.SZ) stated on the investor interaction platform that the company's revenue from directly exporting synthetic biology products such as glutathione and SAM (S-adenosylmethionine) to the USA accounts for about 2%. According to the list of products exempt from Global tariffs and reciprocal tariffs released by the White House, and after preliminary communication with certain customers in the USA, the company's food-grade glutathione, SAM, and PQQ are included in the exemption list. The company will continue to monitor changes in tariff policies and maintain communication with customers.

Gelonghui FinanceApr 8 15:47

Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.

In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.

cls.cnApr 7 08:17

Express News | Shandong Jincheng Pharmaceutical Group: The first phase of the employee stock ownership plan has been completed.

BreakingsApr 3 15:44

Shandong Jincheng Pharmaceutical Group (300233.SZ): In 2024, the company's synthetic nicotine sales are expected to grow year-on-year, and it is actively conducting market promotion.

Gelonghui, on April 1, reported that Shandong Jincheng Pharmaceutical Group (300233.SZ) stated on the investor interaction platform that the sales volume of synthetic nicotine is expected to grow year-on-year in 2024, and the company is actively carrying out market promotion.

Gelonghui FinanceApr 1 15:22